title: Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis:  with special emphasis upon visual safety.
authors.forename: Alison
authors.initials: A
authors.lastname: Huggins
authors.forename: Robert C
authors.initials: RC
authors.lastname: Sergott
mesh_terms: D000284:Administration, Oral; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011409:Propylene Glycols / Q000009:adverse effects / Q000494:pharmacology*; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine